Sangrix names Li Wei Ray director with no holdings

Sangrix Inc. director Li Wei Ray filed an initial ownership report showing no company shares or insider trades currently reported.

Rhea-AI Filing Summary

SANGRIX INC. (ticker BTOG) filed an initial statement of beneficial ownership indicating that Li Wei Ray is a director of the company. The filing does not report any equity holdings or insider transactions by Li Wei Ray as of the filing date.

Key Figures

Directors reported: 1 director Insider transactions reported: 0 transactions Share holdings reported: 0 shares

3 metrics

Directors reported 1 director Number of reporting persons listed as directors in this Form 3

Insider transactions reported 0 transactions Transaction summary shows no insider trades or other reportable events

Share holdings reported 0 shares No common stock or derivative positions reported for Li Wei Ray

Key Terms

Form 3, reporting person, ten percent owner

3 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"Number of reporting persons listed as directors"

ten percent owner regulatory

"not reported as an officer or ten percent owner"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 3 filing disclose for BTOG (Sangrix Inc.)?

It discloses that Li Wei Ray is a director of Sangrix Inc. and serves as an initial statement of beneficial ownership, with no company share holdings or insider transactions reported for this person.

Does Li Wei Ray report owning any BTOG shares in this Form 3?

No. The Form 3 for BTOG reports no equity holdings for Li Wei Ray. The transaction and holding sections are empty, indicating no shares or derivative securities are reported as of this filing.

Are there any insider stock purchases or sales reported for BTOG in this Form 3?

No. The filing shows no insider transactions by Li Wei Ray, with buy, sell, gift, exercise, and other transaction counts all reported as zero in the transaction summary.

What is Li Wei Ray’s role at Sangrix Inc. (BTOG) according to the Form 3?

According to the Form 3, Li Wei Ray is a director of Sangrix Inc. The person is not reported as an officer or ten percent owner in this filing.

Does this BTOG Form 3 mention a Rule 10b5-1 trading plan?

No. The available data indicate no Rule 10b5-1 trading plan is reported for Li Wei Ray in this Form 3, and there are no transactions that would be associated with such a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 09:21 AM Accepted by SEC EDGAR 09/10/2026 - 09:20 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LI WEI RAY

(Last) (First) (Middle)

15 ANCHORVALE CRESCENT, #16-10

(Street)

SINGAPORE 544651

(City) (State) (Zip)

SINGAPORE

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/09/2026

3. Issuer Name and Ticker or Trading Symbol
SANGRIX INC. [ SGRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Wei Ray Li	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)